Iovance Biotherapeutics, Inc. IOVA Operating Cash Flow
Operating Cash Flow at other companies
Other financials
Where this comes from
Reported directly by Iovance Biotherapeutics, Inc. in its filing.
Tagged under the XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities.
The official record: Iovance Biotherapeutics, Inc.’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →
Ask your AI about Iovance Biotherapeutics, Inc.'s operating cash flow.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Iovance Biotherapeutics, Inc.'s operating cash flow?
- Iovance Biotherapeutics, Inc. (IOVA) reported operating cash flow of -$72.07M in Q1 2026.
- How has Iovance Biotherapeutics, Inc.'s operating cash flow changed year-over-year?
- Iovance Biotherapeutics, Inc.'s operating cash flow increased by 30.5% year-over-year, from -$103.69M to -$72.07M.
- What is the long-term trend for Iovance Biotherapeutics, Inc.'s operating cash flow?
- Over 4 years (2021 to 2025), Iovance Biotherapeutics, Inc.'s operating cash flow has grown at a 7.3% compound annual growth rate (CAGR), from -$227.94M to -$302.41M.
- What does operating cash flow mean?
- Total cash generated by or used in core business operations — the single most important cash flow metric for assessing business health.